Klimovsky Judith V. Insider Trades

Insider Trading History

Track insider trading activity for Klimovsky Judith V.. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Bio-Techne
Bio-Techne TECH
Director
Holding Value $213k 3,782 shares
Last Trade
Oct 30, 2025 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$330k 5,417 shares
$60.96
$56.26
Bio-Techne
Bio-Techne TECH
Director
Holding Value $198k 3,511 shares
Last Trade
Oct 24, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$240k 3,511 shares
$68.37
$56.26
Bio-Techne
Bio-Techne TECH
Director
Holding Value $90.6k 1,610 shares
Last Trade
May 01, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$118k 1,610 shares
$73.46
$56.26
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals BLCM
Director
Holding Value $8.24k 110,098 shares
Last Trade
Jan 03, 2023 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$50.1k 60,414 shares
$0.83
$0.07
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals BLCM
Director
Holding Value $3.72k 49,684 shares
Last Trade
Sep 01, 2022 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$39.7k 35,082 shares
$1.13
$0.07
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals BLCM
Director
Holding Value $1.12k 15,000 shares
Last Trade
Jun 15, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$33.3k 30,000 shares
$1.11
$0.07
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals BLCM
Director
Holding Value $0 0 shares
Last Trade
Jan 04, 2022 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$866 566 shares
$1.53
$0.07
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals BLCM
Director
Holding Value $1.09k 14,602 shares
Last Trade
Jan 04, 2022 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$22.3k 14,602 shares
$1.53
$0.07
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals BLCM
Director
Holding Value $42.3 566 shares
Last Trade
Jul 01, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$1.88k 566 shares
$3.33
$0.07
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals BLCM
Director
Holding Value $486 6,500 shares
Last Trade
Jun 15, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$19.8k 6,500 shares
$3.05
$0.07
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals BLCM
Director
Holding Value $1.05k 14,036 shares
Last Trade
Jan 04, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$47.7k 14,036 shares
$3.40
$0.07
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals BLCM
Director
Holding Value $486 6,500 shares
Last Trade
Jun 15, 2020 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$54.7k 6,500 shares
$8.42
$0.07
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals BLCM
Director
Holding Value $1.87k 25,000 shares
Last Trade
Jun 13, 2019 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$490k 25,000 shares
$19.60
$0.07
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals BLCM
Director
Holding Value $3.74k 50,000 shares
Last Trade
Dec 20, 2018 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$4.2M 125,000 shares
$33.60
$0.07

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up